GlaxoSmithKline Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹1440
- Today's High:
- ₹1480
- Open Price:
- ₹1460.05
- 52W Low:
- ₹1200.4016
- 52W High:
- ₹1474.1
- Prev. Close:
- ₹1460.25
- Volume:
- 4469
Company Statistics
- Market Cap.:
- ₹245.13 billion
- Book Value:
- 102.787
- Revenue TTM:
- ₹32.68 billion
- Operating Margin TTM:
- 22.73%
- Gross Profit TTM:
- ₹18.99 billion
- Profit Margin:
- 19.08%
- Return on Assets TTM:
- 11.75%
- Return on Equity TTM:
- 27.59%
Company Profile
GlaxoSmithKline Pharmaceuticals Limited had its IPO on under the ticker symbol GLAXO.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. GlaxoSmithKline Pharmaceuticals Limited has a staff strength of 3,680 employees.
Stock update
Shares of GlaxoSmithKline Pharmaceuticals Limited opened at ₹1460.05 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹1440 - ₹1480, and closed at ₹1464.4.
This is a +0.28% increase from the previous day's closing price.
A total volume of 4,469 shares were traded at the close of the day’s session.
In the last one week, shares of GlaxoSmithKline Pharmaceuticals Limited have increased by +2.78%.
GlaxoSmithKline Pharmaceuticals Limited's Key Ratios
GlaxoSmithKline Pharmaceuticals Limited has a market cap of ₹245.13 billion, indicating a price to book ratio of 15.5061 and a price to sales ratio of 6.8614.
In the last 12-months GlaxoSmithKline Pharmaceuticals Limited’s revenue was ₹32.68 billion with a gross profit of ₹18.99 billion and an EBITDA of ₹7.82 billion. The EBITDA ratio measures GlaxoSmithKline Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, GlaxoSmithKline Pharmaceuticals Limited’s operating margin was 22.73% while its return on assets stood at 11.75% with a return of equity of 27.59%.
In Q2, GlaxoSmithKline Pharmaceuticals Limited’s quarterly earnings growth was a positive 10.9% while revenue growth was a positive 2.2%.
GlaxoSmithKline Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 39.2354
- PEG
Its diluted EPS in the last 12-months stands at ₹36.88 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GlaxoSmithKline Pharmaceuticals Limited’s profitability.
GlaxoSmithKline Pharmaceuticals Limited stock is trading at a EV to sales ratio of 6.4569 and a EV to EBITDA ratio of 24.4241. Its price to sales ratio in the trailing 12-months stood at 6.8614.
GlaxoSmithKline Pharmaceuticals Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 86.91%.
Balance sheet and cash flow metrics
- Total Assets
- ₹33.27 billion
- Total Liabilities
- ₹13.26 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 86.91%
GlaxoSmithKline Pharmaceuticals Limited ended 2024 with ₹33.27 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹33.27 billion while shareholder equity stood at ₹17.41 billion.
GlaxoSmithKline Pharmaceuticals Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹13.26 billion in other current liabilities, in common stock, ₹8.11 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹349.40 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
GlaxoSmithKline Pharmaceuticals Limited’s total current assets stands at ₹24.94 billion while long-term investments were ₹0 and short-term investments were ₹17.77 billion. Its net receivables were ₹1.92 billion compared to accounts payable of ₹4.28 billion and inventory worth ₹4.60 billion.
In 2024, GlaxoSmithKline Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, GlaxoSmithKline Pharmaceuticals Limited paid ₹0.87 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹1464.4
- 52-Week High
- ₹1474.1
- 52-Week Low
- ₹1200.4016
- Analyst Target Price
- ₹
GlaxoSmithKline Pharmaceuticals Limited stock is currently trading at ₹1464.4 per share. It touched a 52-week high of ₹1474.1 and a 52-week low of ₹1474.1. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1414.72 and 200-day moving average was ₹1313.1 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7556.8% of the company’s stock are held by insiders while 1081.5% are held by institutions.
Frequently Asked Questions About GlaxoSmithKline Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.